Literature DB >> 25280544

Association of a disintegrin and metalloprotease 33 (ADAM33) gene polymorphisms with the risk of COPD: an updated meta-analysis of 2,644 cases and 4,804 controls.

Deng-Chuan Zhou1, Cheng-Fan Zhou, Sam Toloo, Tong Shen, Shi-Lu Tong, Qi-Xing Zhu.   

Abstract

A series of observational studies have been made to investigate the association of the ADAM33 gene polymorphisms with the risk of COPD, but their results were conflicting. Therefore, we performed an updated meta-analysis to quantitatively summarize the associations of ADAM33 gene polymorphisms with the risk of COPD. Thirteen case-control studies referring to nine SNPs were identified: V4 (rs2787094), T+1 (rs2280089), T2 (rs2280090), T1 (rs2280091), S2 (rs528557), S1 (rs3918396), Q-1 (rs612709), F+1 (rs511898) and ST+5 (rs597980). A dominant model (AA+Aa vs. aa), recessive model (AA vs. Aa+aa), additive model (AA vs. aa) and allelic model (A vs. a) were used to evaluate the association of ADAM33 polymorphism with the risk of COPD. The results indicated that significant associations were found for ADAM33 T1, T2, S1, Q-1, F+1 and ST+5 polymorphisms associated with the risk of COPD in different populations. However, no significant associations were found for V4, T+1 and S2 polymorphisms with the risk of COPD in all genetic models, even in the subgroup analysis by ethnicity. This meta-analysis provided evidence that the ADAM33 T1, T2, S1, Q-1, F+1 and ST+5 six locus polymorphisms association with the risk of COPD. Furthermore, T2, Q-1 and ST+5 indicated an association with the risk of COPD in the European populations, whereas T1, T2, S1, F+1 and Q-1 indicated an association with the risk of COPD in the Asian populations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25280544     DOI: 10.1007/s11033-014-3782-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  26 in total

1.  Identification and characterization of novel mouse and human ADAM33s with potential metalloprotease activity.

Authors:  Tsuyoshi Yoshinaka; Kazuhiro Nishii; Kouji Yamada; Hirohide Sawada; Eiji Nishiwaki; Katherine Smith; Kohichiro Yoshino; Hiroshi Ishiguro; Shigeki Higashiyama
Journal:  Gene       Date:  2002-01-09       Impact factor: 3.688

2.  Association of ADAM33 gene with susceptibility to COPD in Tibetan population of China.

Authors:  Jinling Xiao; Jianyu Han; Xinyan Wang; Demi Hua; Dongju Su; Yongxia Bao; Fuzhen Lv
Journal:  Mol Biol Rep       Date:  2010-12-15       Impact factor: 2.316

3.  [Association of the MMP3, MMP9, ADAM33 and TIMP3 genes polymorphic markers with development and progression of chronic obstructive pulmonary disease].

Authors:  G F Korytina; O S Tselousova; L Z Akhmadishina; E V Victorova; Sh Z Zagidullin; T V Victorova
Journal:  Mol Biol (Mosk)       Date:  2012 May-Jun

4.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

5.  Developing COPD: a 25 year follow up study of the general population.

Authors:  A Løkke; P Lange; H Scharling; P Fabricius; J Vestbo
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

6.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.

Authors:  N R Anthonisen; J E Connett; J P Kiley; M D Altose; W C Bailey; A S Buist; W A Conway; P L Enright; R E Kanner; P O'Hara
Journal:  JAMA       Date:  1994-11-16       Impact factor: 56.272

7.  Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness.

Authors:  Paul Van Eerdewegh; Randall D Little; Josée Dupuis; Richard G Del Mastro; Kathy Falls; Jason Simon; Dana Torrey; Sunil Pandit; Joyce McKenny; Karen Braunschweiger; Alison Walsh; Ziying Liu; Brooke Hayward; Colleen Folz; Susan P Manning; Alicia Bawa; Lisa Saracino; Michelle Thackston; Youssef Benchekroun; Neva Capparell; Mei Wang; Ron Adair; Yun Feng; JoAnn Dubois; Michael G FitzGerald; Hui Huang; René Gibson; Kristina M Allen; Alex Pedan; Melvyn R Danzig; Shelby P Umland; Robert W Egan; Francis M Cuss; Steuart Rorke; Joanne B Clough; John W Holloway; Stephen T Holgate; Tim P Keith
Journal:  Nature       Date:  2002-07-10       Impact factor: 49.962

8.  Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2.

Authors:  Farrah Kheradmand; Kirtee Rishi; Zena Werb
Journal:  J Cell Sci       Date:  2002-02-15       Impact factor: 5.285

9.  Role of ADAM33 gene and associated single nucleotide polymorphisms in asthma.

Authors:  Neeraj Sharma; Priya Tripathi; Shally Awasthi
Journal:  Allergy Rhinol (Providence)       Date:  2011-04

10.  Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers.

Authors:  Alireza Sadeghnejad; Jill A Ohar; Siqun L Zheng; David A Sterling; Gregory A Hawkins; Deborah A Meyers; Eugene R Bleecker
Journal:  Respir Res       Date:  2009-03-12
View more
  7 in total

Review 1.  Immune-related gene polymorphisms in pulmonary diseases.

Authors:  Dhirendra P Singh; Prathyusha Bagam; Malaya K Sahoo; Sanjay Batra
Journal:  Toxicology       Date:  2017-03-30       Impact factor: 4.221

Review 2.  Genetic Variants Associated with Chronic Obstructive Pulmonary Disease Risk: Cumulative Epidemiological Evidence from Meta-Analyses and Genome-Wide Association Studies.

Authors:  Caiyang Liu; Ran Ran; Xiaoliang Li; Gaohua Liu; Xiaoyang Xie; Ji Li
Journal:  Can Respir J       Date:  2022-06-09       Impact factor: 2.130

Review 3.  Novel aspects of pathogenesis and regeneration mechanisms in COPD.

Authors:  Edvardas Bagdonas; Jovile Raudoniute; Ieva Bruzauskaite; Ruta Aldonyte
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-06-02

Review 4.  The etiologic origins for chronic obstructive pulmonary disease.

Authors:  Xinwei Huang; Xi Mu; Li Deng; Aili Fu; Endong Pu; Tao Tang; Xiangyang Kong
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-05-27

5.  The strong correlation between ADAM33 expression and airway inflammation in chronic obstructive pulmonary disease and candidate for biomarker and treatment of COPD.

Authors:  Muhammad Fachri; Mochammad Hatta; Muhammad Nasrum Massi; Arif Santoso; Tri Ariguntar Wikanningtyas; Ressy Dwiyanti; Ade Rifka Junita; Muhammad Reza Primaguna; Muhammad Sabir
Journal:  Sci Rep       Date:  2021-11-30       Impact factor: 4.379

6.  Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life.

Authors:  Elizabeth R Davies; Joanne F C Kelly; Peter H Howarth; David I Wilson; Stephen T Holgate; Donna E Davies; Jeffrey A Whitsett; Hans Michael Haitchi
Journal:  JCI Insight       Date:  2016-07-21

7.  Comparison and development of machine learning tools for the prediction of chronic obstructive pulmonary disease in the Chinese population.

Authors:  Xia Ma; Yanping Wu; Ling Zhang; Weilan Yuan; Li Yan; Sha Fan; Yunzhi Lian; Xia Zhu; Junhui Gao; Jiangman Zhao; Ping Zhang; Hui Tang; Weihua Jia
Journal:  J Transl Med       Date:  2020-03-31       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.